Omeros Corp (OQ:OMER)
Business Focus: Bio Therapeutic Drugs
|
| |
| Latest 10 SEC filings (by transaction date) for OMER within the last 6 months | [?] |
 Amended Filing  Footnote and/or Remark | |
As of 11:59pm ET April 23rd, 2024
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
|---|---|---|---|---|---|---|---|
| Nov 21/23 | Nov 17/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | P - Open market or private purchase | 15,000 | $1.68 |
| Nov 17/23 | Nov 15/23 | Demopulos Peter A MD | Direct Ownership | Common Stock | P - Open market or private purchase | 10,000 | $1.53 |
| Nov 15/23 | Nov 14/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 25,000 | $1.44 |
| Nov 15/23 | Nov 13/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 37,500 | $1.29 |
| Sep 27/23 | Sep 22/23 | Demopulos Gregory A MD | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 715,000 | |
| Sep 27/23 | Sep 22/23 | Jacobsen Michael A | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 100,000 | |
| Sep 27/23 | Sep 22/23 | Cancelmo Peter B | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 100,000 | |
| Sep 14/23 | Sep 12/23 | Bumol Thomas F. | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 10,000 | $3.31 |
| Jun 27/23 | Jun 23/23 | Hanish Arnold C | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 15,000 | |
| Jun 27/23 | Jun 23/23 | Hood Leroy E. MD PhD | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 15,000 | |
| Sign up or login above to see all SEC filings within the past 6 months. | |||||||
| Latest 10 SEC filings (by filing date) for OMER within the last 6 months | [?] |
| Amended Filing Footnote and/or Remark | |
As of 11:59pm ET April 23rd, 2024
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
|---|---|---|---|---|---|---|---|
| Nov 21/23 | Nov 17/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | P - Open market or private purchase | 15,000 | $1.68 |
| Nov 17/23 | Nov 15/23 | Demopulos Peter A MD | Direct Ownership | Common Stock | P - Open market or private purchase | 10,000 | $1.53 |
| Nov 15/23 | Nov 14/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 25,000 | $1.44 |
| Nov 15/23 | Nov 13/23 | Demopulos Gregory A MD | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 37,500 | $1.29 |
| Sep 27/23 | Sep 22/23 | Demopulos Gregory A MD | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 715,000 | |
| Sep 27/23 | Sep 22/23 | Jacobsen Michael A | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 100,000 | |
| Sep 27/23 | Sep 22/23 | Cancelmo Peter B | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 100,000 | |
| Sep 14/23 | Sep 12/23 | Bumol Thomas F. | Indirect Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 10,000 | $3.31 |
| Jun 27/23 | Jun 23/23 | Hanish Arnold C | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 15,000 | |
| Jun 27/23 | Jun 23/23 | Hood Leroy E. MD PhD | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 15,000 | |
| Sign up or login above to see all SEC filings within the past 6 months. | |||||||
| Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors
| Competitors with Recent Insider Filings |
| Neurocrine Biosciences (OQ:NBIX) |
| Regeneron Pharmaceuticals (OQ:REGN) |
| Madrigal Pharmaceuticals (OQ:MDGL) |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.